Olivier De Beaumont

Meylan, 38240, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Magnetic resonance imaging-based biodistribution of theranostic AGuIX nanoparticles in the NANORAD 2 clinical trial for brain metastases.

Magnetic resonance imaging-based biodistribution of theranostic AGuIX nanoparticles in the NANORAD 2 clinical trial for brain metastases.

Journal: Journal of neuro-oncology
Published: December 19, 2025

Author Correction: Quantifying gadolinium-based nanoparticle uptake distributions in brain metastases via magnetic resonance imaging.

Author Correction: Quantifying gadolinium-based nanoparticle uptake distributions in brain metastases via magnetic resonance imaging.

Journal: Scientific reports
Published: March 04, 2025

Mechanisms of Action of AGuIX as a Pan-Cancer Nano-Radiosensitizer: A Comprehensive Review.

Mechanisms of Action of AGuIX as a Pan-Cancer Nano-Radiosensitizer: A Comprehensive Review.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: February 19, 2025

NANO-GBM trial of AGuIX nanoparticles with radiotherapy and temozolomide in the treatment of newly diagnosed Glioblastoma: Phase 1b outcomes and MRI-based biodistribution.

NANO-GBM trial of AGuIX nanoparticles with radiotherapy and temozolomide in the treatment of newly diagnosed Glioblastoma: Phase 1b outcomes and MRI-based biodistribution.

Journal: Clinical and translational radiation oncology
Published: May 16, 2024

Phase I/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol).

Phase I/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol).

Journal: BMC cancer
Published: March 31, 2023

A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours.

A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours.

Journal: British journal of cancer
Published: May 12, 2020

In allergic rhinitis, work, classroom and activity impairments are weakly related to other outcome measures.

In allergic rhinitis, work, classroom and activity impairments are weakly related to other outcome measures.

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Published: April 28, 2016

Comparison of outcome measures in allergic rhinitis in children, adolescents and adults.

Comparison of outcome measures in allergic rhinitis in children, adolescents and adults.

Journal: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
Published: March 04, 2016

House dust mite sublingual immunotherapy is safe in patients with mild-to-moderate, persistent asthma: a clinical trial.

House dust mite sublingual immunotherapy is safe in patients with mild-to-moderate, persistent asthma: a clinical trial.

Journal: Allergy
Published: October 11, 2015

Allergen Immunotherapy (AIT): a prototype of Precision Medicine.

Allergen Immunotherapy (AIT): a prototype of Precision Medicine.

Journal: The World Allergy Organization journal
Published: June 23, 2015

Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen-allergic patients.

Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen-allergic patients.

Journal: Allergy
Published: March 27, 2015

Five-grass pollen immunotherapy tablet: an update on the latest findings from clinical trials: an interview with Olivier de Beaumont.

Five-grass pollen immunotherapy tablet: an update on the latest findings from clinical trials: an interview with Olivier de Beaumont.

Journal: Immunotherapy
Published: November 28, 2014
Showing 1-12 of 21

Last Updated: 09/26/2026